Skip to main content
. 2021 Apr 16;2021:6663782. doi: 10.1155/2021/6663782

Figure 6.

Figure 6

DNMT1 repressed CDKN2A expression by promoter hypermethylation. (a) MSP results showed the methylation status of CDKN2A following fenofibrate treatment. (M: reactions using CDKN2A primers specific for methylated CpG sites; U: reactions using CDKN2A primers specific for unmethylated CpG sites). (b) The mRNA expression of DNMT1 and CDKN2A in cells was measured using qRT-PCR. Data was presented as mean ± SD (NC: untreated cell; 5-Aza: 5-azacytidine treated cell; DNMT1 oe: DNMT1 overexpression cell; ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001). (c) The protein expression of CDKN2A and DNMT1 in SW480 and HCT116 cells was measured using western blot.